[Changes of plasminogen activator inhibitor-1 and D-dimer during continuous blood purification and related factors]

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Jan;39(1):67-72. doi: 10.11817/j.issn.1672-7347.2014.01.012.
[Article in Chinese]

Abstract

Objective: To observe the changes of plasminogen activator inhibitor-1 and D-dimer during continuous blood purification (CBP) and related factors.

Methods: Sixteen patients who were diagnosed with multiple organ dysfunction syndrome (MODS) were randomly divided into 2 groups: 8 patients received standard continuous blood purification with heparin anticoagulation, and the other 8 received CBP without anticoagulation. Ten normal blood samples were collected from healthy volunteers as controls. All patients underwent CBP for 8 h. Blood was taken from those patients at 0, 15, 60, 120 and 480 min during the CBP. Plasma plasminogen activator inhibitor-1, D-dimer and serum TNF-α and IL-1β were measured by ELISA.

Results: Plasma levels of PAI-1 and D-dimer were increased significantly compared with those in the control group (P<0.05). Plasma level of PAI-1 was reduced (P<0.05) and D-dimer was increased (P<0.05) after the CBP. The level of plasma PAI-1 in the heparin group was significant reduced compared with the group of CBP without anticoagulation (P<0.05). There was negative correlation between the level of PAI-1 and the dosage of heparin used during a CBP session in the heparin group (r=-0.746, P<0.001).

Conclusion: The level of PAI-1 and D-dimer is higher in patients with MODS than that in the normal controls. After the CBP treatment, there is significant decrease in PAI-1 and increase in D-dimer in both groups. Heparin used during CBP can reduce PAI-1 which intensifies its function of anticoagulation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anticoagulants / therapeutic use
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Heparin / therapeutic use
  • Humans
  • Interleukin-1beta / blood
  • Plasminogen Activator Inhibitor 1 / blood*
  • Renal Dialysis*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • Interleukin-1beta
  • Plasminogen Activator Inhibitor 1
  • Tumor Necrosis Factor-alpha
  • fibrin fragment D
  • Heparin